European Journal of Heart Failure

Article	Citations
Abstract	365
Adrenomedullin as a Marker of Hypoxia, Not Hypoperfusion. Letter Regarding the Article ‘Biologically Active Adrenomedullin as a Marker for Residual Congestion and Early Rehospitalization in Patients H	212
Issue Information	181
Identifying Reliable Biomarkers for Pulmonary Congestion: Toward a Close Yet Sustainable Heart Failure Follow-Up	171
Salt Repletion and Diuretic Response: The Role of Serum Chloride. A Post-hoc Analysis of the SALT-HF Trial on Furosemide and Hypertonic Saline Solution Administration in Ambulatory Patients with Worse	150
Machine learning to reveal hidden HFpEF: promise, pitfalls, and next steps	141
Risk factors for the development of heart failure in patients with or without prior myocardial infarction	136
Heart failure: age is no excuse for complacency	128
	119
Reply to ‘Morphine use in acute cardiogenic pulmonary oedema: is MIMO trial enough to change practice?’	114
Issue Information	110
Striving for the ‘Perfect’ Definition of Iron Deficiency in Heart Failure	91
Tafamidis in Patients with Severe Heart Failure due to Transthyretin Amyloidosis Cardiomyopathy: Improved Long-Term Survival	88
Rationale and Design of the ESC Heart Failure III Registry – Implementation and Discovery	85
Effect of Dapagliflozin on Health Status and Quality of Life Across the Spectrum of Ejection Fraction: Participant-Level Pooled Analysis from the DAPA-HF and DELIVER Trials	84
Association Between Liver Fibrosis, Plasma Volume Status, and Cardiovascular Mortality: The Hiroshima Study on Glucose Metabolism and Cardiovascular Diseases	80
Clonal hematopoiesis is linked to increased risks of all-cause mortality, cardiovascular death, and bleeding complications in patients with atrial fibrillation	79
Exercise Catheterization in Adults Post-Fontan with Normal and Abnormal Haemodynamic Criteria: Insights Into Normal Fontan Physiology	78
Percutaneous Repair of Moderate-to-Severe or Severe Functional Mitral Regurgitation in Patients with Symptomatic Heart Failure: Baseline Characteristics of Patients in the RESHAPE-HF2 Trial and Compar	78
Reply to the letter regarding the article ‘Are mechanical circulatory supports the forgotten aspect in the implementation of therapies for heart failure?’	75
Response to Letter EURJHF-25-1455	74
Culture, Ethnicity, and Socio-Economic Status as Determinants of the Management of Patients with Advanced Heart Failure who Need Palliative Care: A Clinical Consensus Statement from the Heart Failure	73
Are Left Ventricular Ejection Fraction Phenotypes Meaningful in Acute Heart Failure?	72
Applying the ‘Touch-and-Go’ Concept to Mineralocorticoid Receptor Antagonists: A Paradigm Shift in Routine Heart Failure Management	70
Characteristics and Outcomes of Patients with a History of Cancer Recruited to Heart Failure Trials	69

Dissecting the Heart Failure Phenotype Through Phenomics	67
Issue Information	67
Letter Regarding the Article ‘Employment of Artificial Intelligence for an Unbiased Evaluation Regarding the Recovery of Right Ventricular Function After Mitral Valve Transcatheter Edge-To-Edge Repair	66
Abstract	66
Cardiovascular Magnetic Resonance-Estimated Pulmonary Capillary Wedge Pressure, Congestion Markers, and Effect of Empagliflozin in Patients with Heart Failure with Reduced Ejection Fraction and Dysgly	66
Incidence and Predictors of Weaning Failure From Veno-Arterial Extracorporeal Membrane Oxygenation Therapy in Patients With Cardiogenic Shock	66
Determinants of Submaximal Exercise Intolerance in Patients with Heart Failure and Preserved Ejection Fraction: Insights from the Lactate Threshold	65
Expanding the Horizon of Medication Adherence Strategies in Acutely Decompensated Heart Failure. Letter Regarding the Article ‘Medication Adherence in Patients with Acutely Decompensated Heart Failure	65
Finerenone, Chronic Obstructive Pulmonary Disease, and Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial	64
Clinical Profiles and Prognostic Impact of Residual Intravascular and Tissue Congestion in Acute Heart Failure	64
Left ventricular volume and maximal functional capacity in heart failure with preserved ejection fraction: Size matters	64
Letter regarding the article ‘Clinical profiles and prognostic impact of residual intravascular and tissue congestion in acute heart failure’	63
Heart failure in pregnancy: where the 2025 ESC Guidelines ‘cardiovascular disease and pregnancy’ illuminate—and where shadows remain	62
Subclinical atrial fibrillation and the risk of heart failure: insights from ARTESiA	61
Exercise cardiac magnetic resonance biventricular volumetric reserve in heart failure with preserved ejection fraction	61
Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial	60
Time-Varying Analyses of Survival and Outcomes in Patients with HeartMate 3 Left Ventricular Assist Devices	60
Decongestion Strategies In Patients Presenting with Acutely Decompensated Heart Failure: A Worldwide Survey Among Physicians	60
Atrial Cardiomyopathy: From Healthy Atria to Atrial Failure. A Clinical Consensus Statement of the Heart Failure Association of the ESC	58
Burst Steroid Therapy for Acute Heart Failure: The CORTAHF Randomized, Open-Label, Pilot Trial	58
Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR Trial	57
Effect of Sacubitril/Valsartan in Heart Failure with Preserved Ejection Fraction Across the Age Spectrum in PARAGON-HF	56
Similarities and Distinctions Between Acetazolamide and Sodium–Glucose Cotransporter 2 Inhibitors in Patients with Acute Heart Failure: Key Insights Into ADVOR and EMPULSE	56
Digitalis – back on centre stage for HFrEF	55
Use of Mechanical Circulatory Support in Patients with Non-Ischaemic Cardiogenic Shock	55
Corrigendum to ‘Congestion in Heart Failure: A Circulating Biomarker-Based Perspective’ and Articles Listed Below	55
Heart Failure Improvement, Remission, and Recovery: A European Journal of Heart Failure Expert Consensus Document	55
Erythropoietic Response After Intravenous Iron in Patients with Heart Failure and Reduced Ejection Fraction with and Without Background Treatment with Sodium–Glucose Cotransporter 2 Inhibitors	53
Sacubitril/Valsartan Versus Enalapril in Chronic Chagas Cardiomyopathy with Heart Failure: Baseline Characteristics of the PARACHUTE-HF Trial	53
Finerenone According to Insulin Resistance in Heart Failure: Insights from the FINEARTS-HF Trial	53
Weight Change and Clinical Outcomes in Heart Failure with Reduced Ejection Fraction: Insights from EMPEROR-Reduced	53
Predicting Survival in Patients with Severe Heart Failure: Risk Score Validation in the HELP-HF Cohort	52
404-Error “Disease Not Found”: Unleashing the Translational Potential of -Omics Approaches Beyond Traditional Disease Classification in Heart Failure Research	52
Issue Information	51
July 2023 at a Glance: Heart Failure with Preserved Ejection Fraction and Comorbidities	51
Low Blood Pressure and the Effect of Empagliflozin in Acute Heart Failure: An EMPULSE Analysis	51
Aortic Valve Disease and Heart Failure with Mildly Reduced Ejection Fraction: New Insights and Pending Questions	51
	50
The dangerous liaison between epicardial adipose tissue and heart failure with preserved ejection fraction	50
Predicting worsening heart failure with preserved ejection fraction from non‐invasive exercise testing	50
Issue Information	50
Cardiopulmonary functional capacity: another piece of the puzzle of sodium–glucose cotransporter 2 inhibition in heart failure?	50
Effect of the cardiac myosin activator omecamtiv mecarbil on ventricular arrhythmias, cardiac arrest, and sudden death in heart failure with reduced ejection fraction: the GALACTIC-HF trial	49
Reply to ‘A clinical classification method with outstanding advantages for quickly identifying hazardous types’	49
Correction to “Use of Guideline-Recommended Medical Therapy in Patients with Heart Failure and Chronic Kidney Disease: from Physician's Prescriptions to Patient's Dispensations, Medication Adherence a	48
Efficacy and Safety of Finerenone in Patients with Chronic Kidney Disease and Type 2 Diabetes By Diuretic Use: A FIDELITY Analysis	48
Letter Regarding the Article ‘Association Between Antecedent Myocardial Infarction and Heart Failure with Preserved Versus Reduced Ejection Fraction’	48
Health Status Across Major Subgroups of Patients with Heart Failure and Preserved Ejection Fraction	47
Integrated Trajectories of Systolic and Diastolic Function Differentially Associate with Risk for Heart Failure with Preserved and Reduced Ejection Fraction and Proteomic Profiles	47
The Cost-Effectiveness of Dapagliflozin in Heart Failure with Preserved or Mildly Reduced Ejection Fraction: A European Health-Economic Analysis of the DELIVER Trial	47

Diagnostic Pathways to Wild-Type Transthyretin Amyloid Cardiomyopathy: A Multicentre Network Study	47
A novel cardio-vascular media enable to assess the complexity of multicellular organoids	47
Letter Regarding the Article ‘Efficacy and Safety of Angiotensin Receptor–Neprilysin Inhibition in Heart Failure Patients with End-Stage Kidney Disease on Maintenance Dialysis: A Systematic Review and	47
Effect of Long-Term Tafamidis Treatment on Health-Related Quality of Life in Patients with Transthyretin Amyloid Cardiomyopathy	46
Impact of multicomponent exercise training in older individuals with and without heart failure with reduced ejection fraction – the role of functional capacity and novel biomarkers	46
Serial Direct Sodium Removal in Patients with Heart Failure and Diuretic Resistance	46
Normal and Excessive Muscle Sympathetic Nerve Activity in Heart Failure: Implications for Future Trials of Therapeutic Autonomic Modulation	46
Landscape of Glycolytic Metabolites and Their Regulating Proteins in Myocardium from Human Heart Failure with Preserved Ejection Fraction	46
Remote Patient Management of Heart Failure Across the Ejection Fraction Spectrum: A Pre-Specified Analysis of the TIM-HF2 Trial	45
Iron deficiency definitions and their clinical and prognostic associations across the spectrum of left ventricular ejection fraction in heart failure	45
Indexing left ventricular end‐systolic dimension to body size: Association with mortality in patients with degenerative mitral regurgitation	44
Sex Differences in the Generalizability of Randomized Clinical Trials in Heart Failure with Reduced Ejection Fraction	44
Late Diagnosis in Cancer Sparks Outrage—So Why Not Heart Failure?	44
The Different Risk of New-Onset, Chronic, Worsening, and Advanced Heart Failure: A Systematic Review and Meta-Regression Analysis	44
Reply to ‘Is Sodium Chloride Supplementation Ready for Clinical Practice in Acute Heart Failure?’	43
An Individual Treatment Effect Approach to Predict Response to Mineralocorticoid Receptor Antagonists in Patients with Heart Failure and Reduced Ejection Fraction	43
What's New in Heart Failure? October 2025	43
Letter Regarding the Article ‘Guideline-Directed Medical Therapy for Heart Failure in Arrhythmia-Induced Cardiomyopathy with Improved Left Ventricular Ejection Fraction’	43
Application of a Transthyretin Amyloid Cardiomyopathy Score to Heart Failure with Mildly Reduced or Preserved Ejection Fraction	43
The impact of early surgery on mortality in infective endocarditis complicated by heart failure – How much more data do we need?	42
Comparison of Pulmonary Congestion Severity Using Artificial Intelligence-Assisted Scoring Versus Clinical Experts: A Secondary Analysis of BLUSHED-AHF	42
Corrigendum to “Sex Differences in Proteomic Correlates of Coronary Microvascular Dysfunction Among Patients with Heart Failure and Preserved Ejection Fraction”	42
Letter regarding the article ‘evaluating early cardiology involvement and survival outcomes across NT-proBNP levels: an island-wide retrospective cohort study’	42
No Longer from Pillar to Post: The First Effective Step in Treating Heart Failure with Preserved Ejection Fraction	41
Comparative Effectiveness of Sacubitril/Valsartan Versus Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Patients with De Novo Heart Failure with Mildly Reduced and Preserved	41
Enrolling patients in cardiogenic shock trials: are we missing someone? Insights from the Italian AltShock‐2 registry	41
Reply to the Letter Regarding the Article ‘Head-to-Head Comparison Between Recommendations by the ESC and ACC/AHA/HFSA Heart Failure Guidelines’	40
More than Just a Clinical Syndrome: Biomarkers and Echocardiography Should be Rapidly Advised for Anyone with Suspected Heart Failure!	40
Decreased Left Ventricular Ejection Fraction is Associated with Increased Mortality in Sepsis: A Retrospective Cohort Study	40
Analysing the Accuracy of Pressure Measurements During Exercise with Pulmonary Artery Pressure Sensors – Insights from the ACTION-MEMS Study	40
Predicting Heart Failure: The Promise of Proteomics	40
Changes in Mid-Regional Pro-Adrenomedullin During Treatment with Sacubitril/Valsartan	39
Sodium–glucose cotransporter 2 inhibition, uric acid, and heart failure: correlation without causation?	39
Systemic embolism in transthyretin amyloid cardiomyopathy: how to look into the future	39
Revolutionizing Cardiogenic Shock Treatment: Is the Microaxial Flow Pump the Ultimate Game Changer?	39
Artificial Intelligence in Heart Failure Improving the Efficiency or Dependency on it? Letter Regarding the Article ‘Artificial Intelligence and Heart Failure: A State-of-the-Art Review’	39
Delivering more evidence for the specificities of heart failure with improved ejection fraction: New answers, new questions	39
Impact of COVID-19 in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction Enrolled in the DELIVER Trial	39
Heart Failure After Left Atrial Appendage Occlusion: Insights from the LAAOS III Randomized Trial	39
	39
Withdrawn: Major gaps in the information provided to patients before implantation of cardioverter defibrillators: a prospective patient European evaluation	38
	38
Reporting Quality of Heart Failure Randomized Controlled Trials 2000–2020: Temporal Trends in Adherence to CONSORT Criteria	38
Issue Information	38
Video Thermography Uncovers Relationship Between Volume Status and Temperature in Heart Failure	38
Reply to ‘Sodium–glucose cotransporter 2 inhibitor treatment lowers serum uric acid in patients with heart failure with reduced ejection fraction – lessons from clinical trials’	38
Cost-Effectiveness of Dapagliflozin for Patients with Heart Failure Across the Spectrum of Ejection Fraction: A Pooled Analysis of DAPA-HF and DELIVER Data	37
Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study)	37
Low-Dose Digoxin Improves Cardiac Function in Patients with Heart Failure, Preserved Ejection Fraction and Atrial Fibrillation – the RATE-AF Randomized Trial	37
Biventricular Cardiac Power Reserve in Heart Failure with Preserved Ejection Fraction	36
BET proteins link epigenetic remodeling to impaired autophagy in HFpEF	36
Use of guideline‐recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence and persistence	36
Disproportionate Exercise-Induced Pulmonary Hypertension in Relation to Cardiac Output in Heart Failure with Preserved Ejection Fraction: A Non-Invasive Echocardiographic Study	36
Acute Heart Failure Care – a Consensus Series of an International Experts' Group	35
Diuretics in Pregnancy: Data from the ESC Registry of Pregnancy and Cardiac Disease (ROPAC)	35
Clonal Haematopoiesis is Associated with Major Adverse Cardiovascular Events in Patients with Hypertrophic Cardiomyopathy	35
Hemodynamic changes in response to GLP-1 treatment in ICD and CRT patients: insights from HeartLogic sensor data	35
Surrogate markers of clinical endpoints in clinical trials of heart failure	35
Kidney Injury in Patients with Heart Failure-Related Cardiogenic Shock: Results from an International, Multicentre Cohort Study	35
CDK4/6 inhibitor ribociclib induces cardiotoxicity through impaired E2F1-regulated spliceosome assembly	35
Trends in Heart Failure Mortality in Sweden Between 1997 and 2022	34
The Utilization and Impact of Cardiovascular Specialists on Guideline-Directed Medical Scores: An Analysis of a Diverse, Multi-State, Electronic Health Record-Based Registry	34
Effect of Pulmonary Artery Pressure-Guided Management on Outcomes of Patients with Heart Failure Outside Clinical Trials: A Systematic Review and Meta-Analysis of Real-World Evidence with the CardioME	34
Trajectories in New York Heart Association functional class in heart failure across the ejection fraction spectrum: data from the	34
Long‐term survival after acute heart failure hospitalization: from observation to collaborative interventions	34
Managing Water and Salt Balance in Heart Failure: Is There Anything Else to Consider Other than Diet and Diuretics?	34
Differential Sex-Related Effect of Left Ventricular Ejection Fraction Trajectory on the Risk of Mortality and Heart Failure Readmission Following Hospitalization for Acute Heart Failure: A Longitudina	34
Heart rate modulation in heart failure with preserved ejection fraction: lessons from nature	34
Issue Information	33
On-Treatment Analysis of Torsemide Versus Furosemide for Patients Hospitalized for Heart Failure: A Post-Hoc Analysis of TRANSFORM-HF	33
Cardiac contractility modulation therapy improves health status in patients with heart failure with preserved ejection fraction: a pilot study ( CCM‐HFpEF	33
Issue Information	33
Association of Clonal Haematopoiesis with Heart Failure Incidence and Outcomes: A Systematic Review and Meta-Analysis	33
Remote Pulmonary Artery Pressure-Guided Management of Patients with Heart Failure: A Clinical Consensus Statement of the Heart Failure Association (HFA) of the ESC	33
	33
From evidence to adoption: lessons from the OPTIPHARM-HF registry	33
Reply to the Letter Regarding the Article ‘Clinical Implications of Left Atrial Changes After Optimization of Medical Therapy in Patients with Heart Failure’	32
Concomitant Latent Pulmonary Vascular Disease Leads to Impaired Global Cardiac Performance in Heart Failure with Preserved Ejection Fraction	32
Impact of Age on Clinical Outcomes and Response to Serelaxin in Patients with Acute Heart Failure: An Analysis from the RELAX-AHF-2 Trial	32
Parvovirus B19 – More Than a Bystander in the Prognosis of Non-Ischaemic Heart Failure	32

Issue Information	32
Plasma Soluble Fms-Like Tyrosine Kinase-1, Placental Growth Factor, and Vascular Endothelial Growth Factor System Gene Variants as Predictors of Survival in Heart Failure	32
Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: Treat the Heart, Cherish the Kidney	32
Transcatheter Edge-to-Edge Repair: Fix the Heart, Heal the Liver	31
Correction to  ‘What's New in Heart Failure? May–June 2024’ ,  ‘What's New in Heart Failure? June–July 2024’,  ‘What's New in Heart Failure? August–September 2024’,  ‘The Month in Heart Failure! Septe	31
Cardiac Reverse Remodelling with Vericiguat: Victory or no Victory?	31
Clonal Haematopoiesis of Indeterminate Potential is Associated with Progression of Aortic Valve Stenosis	31
Early Changes in Renal Function During Rapid Up-Titration of Guideline-Directed Medical Therapy Following an Admission for Acute Heart Failure	31
Reply to the Letter Regarding the Article ‘Lower Extremity Lymphatic Flow is Associated with Diuretic Response in Acute Heart Failure’	31
Commentary on ‘effect of glucagon-like peptide-1 receptor agonists on heart failure outcomes and cardiovascular death across varying cardiovascular–kidney-metabolic comorbidity’	30
Lung Ultrasound and Mortality in a Cardiogenic Shock Population: A Prospective Registry-Based Analysis	30
Diuretic Efficiency of a Single Dose of Subcutaneous Versus Oral Furosemide After Heart Failure Hospitalization Across Diuretic Resistance Strata: A Pilot Randomized Controlled Trial	30
Engineering of bidirectional cardiomyocyte-specific promoters to independently express two transgenes in AAV gene therapy	30
The Addition of Vericiguat to Sacubitril/Valsartan Improved the Composite Endpoint. Add a Finishing Touch on Heart Failure Medical Therapy By Vericiguat as Secret Ingredient	30
The Efficacy of Finerenone on Hierarchical Composite Endpoint Analysed Using Win Statistics in Patients with Heart Failure and Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of	30
Clinical features, haemodynamics, and outcomes of heart failure with preserved ejection fraction in coarctation of aorta	30
End-organ Protective Effect of Serelaxin in Patients Hospitalized for Heart Failure: Results of the Biomarker Substudy of Relaxin in Acute Heart Failure-2 (RELAX-AHF-2)	30
Management of Patients with Heart Failure at High Risk of Hyperkalaemia: The CARE-HK in HF Registry	30
Mineralocorticoid receptor antagonists reduce new-onset atrial fibrillation across the cardio-kidney-metabolic spectrum: a meta-analysis of randomized clinical trials	30
Clinical and Plasma Proteomic Characterization of Heart Failure with Supranormal Left Ventricular Ejection Fraction: An Emerging Entity of heart failure	29
Effects of Dapagliflozin According to QRS Duration Across the Spectrum of Left Ventricular Ejection Fraction: An Analysis of DAPA-HF and DELIVER	29
Growth Differentiation Factor-15 and the Effect of Empagliflozin in Heart Failure: Findings from the EMPEROR Program	29
Effect of Vericiguat on Left Ventricular Structure and Function in Patients with Heart Failure with Reduced Ejection Fraction: The VICTORIA Echocardiographic Substudy	29
Evolocumab has no Effects on Heart Failure with Reduced Ejection Fraction Injury Biomarkers: The EVO-HF Trial	28
Finerenone in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction: Rationale and Design of the FINEARTS-HF Trial	28
European Society of Cardiology Quality Indicators for the Care and Outcomes of Adults with Pulmonary Arterial Hypertension. Developed in Collaboration with the Heart Failure Association of the Europea	28
Effect of Allogeneic Adipose Tissue-Derived Mesenchymal Stromal Cell Treatment in Chronic Ischaemic Heart Failure with Reduced Ejection Fraction – the SCIENCE Trial	28
Myocardial Perfusion in Cardiac Amyloidosis	28
Contemporary Insights Into the Epidemiology, Impact and Treatment of Secondary Tricuspid Regurgitation Across the Heart Failure Spectrum	27
Machine Learning Approach to Identify Phenotypes in Patients with Ischaemic Heart Failure with Reduced Ejection Fraction	27
Midazolam versus morphine in acute cardiogenic pulmonary oedema: results of a multicentre, open‐label, randomized controlled trial	27
Heart Failure Hospitalizations and Clinical Outcomes in Patients Undergoing Tricuspid Transcatheter Edge-To-Edge Repair: Insights from EuroTR	27
An alternative path in transthyretin amyloid cardiomyopathy	27
Assessing health status after discharge for decompensated heart failure: a patient‐centred priority	27
Preventive Catheter Ablation for Ventricular Arrhythmias in Patients with End-Stage Heart Failure Referred for Heart Transplantation Evaluation: Rationale for and Design of the CASTLE-VT Trial	27
Diabetic Myocardial Disorder. A Clinical Consensus Statement of the Heart Failure Association of the ESC and the ESC Working Group on Myocardial & Pericardial Diseases	26
Anaemia in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial	26
Neuropeptide Y is Elevated in Heart Failure and is an Independent Predictor of Outcomes	26
Peri-Procedural Management of Transcatheter Mitral Valve Replacement in Patients with Heart Failure	26
When is the time right? Dancing on the tightrope: referral for upgrade to cardiac resynchronization therapy	26
A Roadmap for Therapeutic Discovery in Pulmonary Hypertension Associated with Left Heart Failure. A Scientific Statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on	26
Impact of contemporary guideline-directed medical therapy on secondary mitral and tricuspid regurgitation in heart failure with reduced ejection fraction	26
Natriuretic Peptides, Body Mass Index and Heart Failure Risk: Pooled Analyses of SAVOR-TIMI 53, DECLARE-TIMI 58 and CAMELLIA-TIMI 61	26
Influence of Background Medical Therapy on Efficacy and Safety of Dapagliflozin in Patients with Heart Failure with Improved Ejection Fraction in the DELIVER Trial	26
Bug attack! The rising importance of Chagas disease	26
Transthyretin amyloidosis: the picture is getting clearer	26
Worsening Heart Failure Comes into Focus, Chronic Heart Failure Takes a Backseat	26
Challenges of heart failure pharmacotherapy in obesity	26
Reply to the Letter Regarding the Article ‘Acute Heart Failure After Non-Cardiac Surgery: Incidence, Phenotypes, Determinants and Outcomes’	25
When and How? Two Simple Questions to Determine Cancer Status and Inform Therapeutic Decisions and Trial Design in Heart Failure	25
Pacing Beyond Rhythm – Improving Myocardial Function by Tickling the Heart Electrically?	25
Is it NICE to Measure Natriuretic Peptides After a Hospitalization for Heart Failure?	25
Improve Heart Function to Improve Heart Failure Outcomes: The Disease-Modifying Effects of Spironolactone	25
Implementing the evidence – the true summit of evidence‐based care and the false peak of guidelines	25
Time to Treat the Climate and Nature Crisis as One Indivisible Global Health Emergency	25
Splanchnic Nerve Block with Botulinum Toxin for Therapy of Chronic Heart Failure – Mechanism of Action (SPONGE-HF)	25
Pulmonary Vascular Disease in Heart Failure with Preserved Ejection Fraction: The Evidence Grows	25
Heart Failure Treatment in the Last Years of Life: A Nationwide Study of 364 000 Individuals	25
Letter Regarding the Article ‘Heart Failure with Improved Versus Persistently Reduced Left Ventricular Ejection Fraction: A Comparison of the BIOSTAT-CHF (European) Study with the ASIAN-HF Registry’	25
Impact of Misclassification Bias on Interpretation of Finerenone Efficacy in Chronic Obstructive Pulmonary Disease and Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Critical Appr	24
Reply to the Letter Regarding the Article ‘Association of Clonal Haematopoiesis with Heart Failure Incidence and Outcomes: A Systematic Review and Meta-Analysis’	24
If a Patient Does Not Require Treatment with Loop Diuretics, Do they Really Have Heart Failure?	24
A Second Wind for Digitalis Glycosides in Heart Failure?	24
Sodium Chloride Supplementation in Acute Heart Failure: A Closer Look at SOLVRED-AHF. Letter Regarding the Article ‘Sodium Chloride Versus Glucose Solute as a Volume Replacement Therapy for More Effec	24
Skeletal Muscle and Subcutaneous Fat Quantity as Prognostic Indicators in Cardiac Amyloidosis	24
Changes in Natriuretic Peptide Levels Following Patiromer-Enabled Optimization of Medical Therapy In Heart Failure: A Post Hoc Analysis of the DIAMOND Study	24
The Role of Kidney Disease Progression in Heart Failure Prognosis: Bridging the Evidence Gap for Optimal Management	24
Time to Reconsider the Perception and Management of Hypertensive Heart Disease	23
Device‐based remote monitoring strategies for congestion‐guided management of patients with heart failure: a systematic review and meta‐analysis	23
Albuminuria as a Diagnostic Criterion and a Therapeutic Target in Heart Failure and Other Cardiovascular Disease	23
Establishing living myocardial slices as a preclinical model of ischemia reperfusion injury	23
Right Heart Failure as a Cause of Pulmonary Congestion in Pulmonary Arterial Hypertension	23
Safety and Performance of a Novel Implantable Sensor in the Inferior Vena Cava Under Acute and Chronic Intravascular Volume Modulation	23
Artificial Intelligence Methods for Improved Detection of Undiagnosed Heart Failure with Preserved Ejection Fraction	23
Preclinical development of a Meg3 ASO inhibitor for the treatment of cardiac fibrosis	23
Early changes in estimated glomerular filtration rate post‐initiation of empagliflozin in EMPEROR‐Reduced	23
Integration of Implantable Device Therapy in Patients with Heart Failure. A Clinical Consensus Statement from the Heart Failure Association (HFA) and European Heart Rhythm Association (EHRA) of the Eu	23
Guideline-Directed Medical Therapy for Heart Failure in Arrhythmia-Induced Cardiomyopathy with Improved Left Ventricular Ejection Fraction	23
Tricuspid Regurgitation: Frequency, Clinical Presentation, Management and Outcome Among Patients with Severe Left-Sided Valvular Heart Disease in Europe. Insights from the ESC-EORP Valvular Heart Dise	22
Heart Failure Related Central Sympathetic Activation: Debunking the ‘Holy Grail’?	22
Time for Differential Weight Management in Heart Failure	22
A Machine-Learning-Based Prediction Model in Patients with Takotsubo Syndrome: ‘You can't Stop Change Any More than you can Stop the Suns from Setting!’	22
Characteristics and Outcomes of Patients with Atrial Versus Ventricular Secondary Tricuspid Regurgitation Undergoing Tricuspid Transcatheter Edge-to-Edge Repair – Results from the TriValve Registry	22
Sodium and Potassium Changes During Decongestion with Acetazolamide – A Pre-Specified Analysis from the ADVOR Trial	22
Reply to: ‘What is the Optimal Dose of Neurohormonal Modulators in Patients with Heart Failure? The Higher the Better?’	22
Kidney Involvement in Transthyretin Cardiac Amyloidosis – Role of Urinary Albumin to Creatinine Ratio and Need for Further Evidence Generation	22
Head‐to‐head comparison between recommendations by the ESC and ACC / AHA<	22
Effect of Phosphodiesterase-5 Inhibition on Systemic Right Ventricular Size and Function. A Multicentre, Double-Blind, Randomized, Placebo-Controlled Trial: SERVE	22
The Pharmacist Ally in Heart Failure: Useful When Involved. Letter Regarding the Article ‘Effective Medications can Work Only in Patients Who Take Them: Implications for Post-Acute Heart Failure Care’	22
Persistent High Mortality in Acute Myocardial Infarction-Associated Cardiogenic Shock Despite Early Mechanical Circulatory Support: Need for Stepwise and Integrated Approach of Care	22
Growth Differentiation Factor-15: A Promising Biomarker for Early Detection of Pre-Heart Failure	22
Glucagon-Like Peptide-1 Receptor Agonists Across the Cardiovascular-Kidney-Metabolic Spectrum: One Size Does not Fit All	21
Clustering in Dilated Cardiomyopathy at Initial Evaluation: An Effective Tool for Clinical Stratification	21
Letter Regarding the Article ‘Clinical and Plasma Proteomic Characterization of Heart Failure with Supranormal Left Ventricular Ejection Fraction: An Emerging Entity of Heart Failure’	21
The Chloride Paradigm Shift in Heart Failure: From Neglected ion to Keystone of Precision Diuretic Therapy	21